Please login to the form below

Not currently logged in
Email:
Password:

patritumab

This page shows the latest patritumab news and features for those working in and with pharma, biotech and healthcare.

Daiichi pulls study of patritumab in lung cancer

Daiichi pulls study of patritumab in lung cancer

Daiichi pulls study of patritumab in lung cancer. HER3 inhibitor candidate showed no evidence of efficacy in trial analysis. ... This particular result does not directly affect the science of patritumab in other settings," said Yver.

Latest news

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
PharmiWeb Solutions

PharmiWeb Solutions creates, delivers and manages digital solutions for the pharmaceutical and healthcare segment. From digital marketing, to patient education...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics